Terms: = Breast cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
26 results:
1. Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic Pathways in MCF7 breast cancer Cells Transfected for JTB Protein Silencing.
Jayathirtha M; Jayaweera T; Whitham D; Sullivan I; Petre BA; Darie CC; Neagu AN
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005222
[TBL] [Abstract] [Full Text] [Related]
2. Variation in IL6ST cytokine family function and the potential of IL6 trans-signalling in ERα positive breast cancer cells.
Mosly D; MacLeod K; Moir N; Turnbull A; Sims AH; Langdon SP
Cell Signal; 2023 Mar; 103():110563. PubMed ID: 36565897
[TBL] [Abstract] [Full Text] [Related]
3. ZCCHC14 regulates proliferation and invasion of non-small cell lung cancer through the MAPK-p38 signalling pathway.
Shi X; Han X; Cao Y; Li C; Cao Y
J Cell Mol Med; 2021 Feb; 25(3):1406-1414. PubMed ID: 33345444
[TBL] [Abstract] [Full Text] [Related]
4. Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum.
Appunni S; Rubens M; Ramamoorthy V; Anand V; Khandelwal M; Saxena A; McGranaghan P; Odia Y; Kotecha R; Sharma A
Clin Chim Acta; 2021 Mar; 514():1-7. PubMed ID: 33333043
[TBL] [Abstract] [Full Text] [Related]
5. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract] [Full Text] [Related]
6. BRAF/MEK Pathway is Associated With breast cancer in ER-dependent Mode and Improves ER Status-based cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract] [Full Text] [Related]
7. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
Veenstra C; Karlsson E; Mirwani SM; Nordenskjöld B; Fornander T; Pérez-Tenorio G; Stål O
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1845-1856. PubMed ID: 31025094
[TBL] [Abstract] [Full Text] [Related]
8. Co-expression of nuclear p38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
Johnston SJ; Ahmad D; Aleskandarany MA; Kurozumi S; Nolan CC; Diez-Rodriguez M; Green AR; Rakha EA
BMC Cancer; 2018 Oct; 18(1):1027. PubMed ID: 30352570
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of copy number alterations in primary breast tumors of South African patients and their impact on functional cellular pathways.
Lupicki K; Elifio-Esposito S; Fonseca AS; Weber SH; Sugita B; Langa BC; Pereira SRF; Govender D; Panieri E; Hiss DC; Abdul-Rasool S; Cavalli LR
Int J Oncol; 2018 Dec; 53(6):2745-2757. PubMed ID: 30320392
[TBL] [Abstract] [Full Text] [Related]
10. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.
Rincón-Fernández D; Culler MD; Tsomaia N; Moreno-Bueno G; Luque RM; Gahete MD; Castaño JP
Carcinogenesis; 2018 Mar; 39(3):447-457. PubMed ID: 29272342
[TBL] [Abstract] [Full Text] [Related]
11. 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
Yoda T; Kikuchi K; Miki Y; Onodera Y; Hata S; Takagi K; Nakamura Y; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H; McNamara KM
Mol Cell Endocrinol; 2015 Sep; 413():236-47. PubMed ID: 26170067
[TBL] [Abstract] [Full Text] [Related]
12. The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via erk signaling activation.
Luo ML; Gong C; Chen CH; Hu H; Huang P; Zheng M; Yao Y; Wei S; Wulf G; Lieberman J; Zhou XZ; Song E; Lu KP
Cell Rep; 2015 Apr; 11(1):111-24. PubMed ID: 25818297
[TBL] [Abstract] [Full Text] [Related]
13. Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics.
Horii R; Matsuura M; Dan S; Ushijima M; Uehiro N; Ogiya A; Honma N; Ito Y; Iwase T; Yamori T; Akiyama F
Int J Clin Oncol; 2015 Jun; 20(3):490-8. PubMed ID: 25312293
[TBL] [Abstract] [Full Text] [Related]
14. TRAP1 is involved in BRAF regulation and downstream attenuation of erk phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
Condelli V; Piscazzi A; Sisinni L; Matassa DS; Maddalena F; Lettini G; Simeon V; Palladino G; Amoroso MR; Trino S; Esposito F; Landriscina M
Cancer Res; 2014 Nov; 74(22):6693-704. PubMed ID: 25239454
[TBL] [Abstract] [Full Text] [Related]
15. Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.
Rudraraju B; Droog M; Abdel-Fatah TM; Zwart W; Giannoudis A; Malki MI; Moore D; Patel H; Shaw J; Ellis IO; Chan S; Brooke GN; Nevedomskaya E; Lo Nigro C; Carroll J; Coombes RC; Bevan C; Ali S; Palmieri C
Breast Cancer Res Treat; 2014 Sep; 147(2):295-309. PubMed ID: 25141981
[TBL] [Abstract] [Full Text] [Related]
16. Distinct effects of EGFR ligands on human mammary epithelial cell differentiation.
Mukhopadhyay C; Zhao X; Maroni D; Band V; Naramura M
PLoS One; 2013; 8(10):e75907. PubMed ID: 24124521
[TBL] [Abstract] [Full Text] [Related]
17. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract] [Full Text] [Related]
18. Targeting the PI3K/AKT/mTOR and Raf/MEK/erk pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract] [Full Text] [Related]
19. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer.
Ohotski J; Edwards J; Elsberger B; Watson C; Orange C; Mallon E; Pyne S; Pyne NJ
Int J Cancer; 2013 Feb; 132(3):605-16. PubMed ID: 22733311
[TBL] [Abstract] [Full Text] [Related]
20. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.
Jiang WG; Martin TA; Lewis-Russell JM; Douglas-Jones A; Ye L; Mansel RE
Mol Cancer; 2008 Sep; 7():71. PubMed ID: 18796137
[TBL] [Abstract] [Full Text] [Related]
[Next]
